Stocx Research Club logo ×
Screener Research Unlisted Startup Funding

Krishan Varma    


Surat, India

Having hands on experience in relationship management with a demonstrated history of working with the Banks/NBFCs/Leading Brokerages house etc. Thus, having adequate knowledge of the Indian capital market where we acquire the retail/HNI clients for the MF SIPs/Lump Sum, F&O, Insurance, PMS and help them to make their future life wealthy.

Read More..
Contributor since: 2022

7

Articles

1

Likes

1

Followers

Sumitomo Chemical India Ltd

Q3FY23 Result Analysis


Performance Highlights –9MFY23

- At theindustry level, over all demand, particularly in the domestic market, was sluggish during the quarter, primarily as a result of a delay in sowing due to the extended monsoons and an increase in channel inventory as a result of as lower off take during the kharif season.The  inventory levels were also high, as the level of pest infestation was relatively low.

- Domestic volume growth during the quarter were largely benign due to the challenging environment. However, the decline in demand was partially offset by improved price realization. Sharpe decline in revenue from fungiside segment resulted into modest topline growth.

- The export growth continues to remain robust, while there are some some sing of slowdonw in Latin America due to high channel inventory. Recent capacity expansion investments should help sustain this encouraging trend. The export business has witnessed growth of 39% YoY in 9MFY23.

- 4 insecticide, 1 fungicide, 1 metal phosphide and 3 PGR products launched during 9MFY23.

- The companies efforts to enhance their porduct mix, revamp our distribution reach and scaling up our capacities positions us to deliver consistent results in the future.

- The company is steps to boost growth in both domestic and international markets. In recent years, the company had prioritized filling the gap in thier portfolio, particular for certain crops and pests. 

Q3FY23 and 9MFY23 Financial Performance

Revenue Breakup

---------------------------------------------------

Sumitomo's Company Overview

Manufacturing Facilities

Capex Plan

Focus on R&D

3 fully equipped, DSIR approved R&D labs located at Mumbai, Bhavnagar and Gajod capable of synthesis, technical product and formulation development

R&D Team comprises of 75+ qualified and dedicated engineers & scientists of which 10+ are PhDs with more than 15 years of Experience

25+ patents granted across various geographies; 9 applications filed.

Product Pipeline

  • Multiple products coming from initiatives
  • Global Speciality Proprietary products to be launched in India
  • New combination products/pre-mixtures currently under development for domestic and exports
  • Off-patent products under development for domestic and exports
  • Technical products approved for manufacturing and exports

R&D facilities to gain capability for creating new processes and new combinations using SCC Japan’s chemistries which would help improve  production processes and efficiency.

Full Year Financial Highlights

 

 

Disclosure:

I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Business relationship disclosure:

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Stocx Research Club). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure:

Sources of the data - Company's Investor Presentation and Press Release. Disclosure - This is not a recommendation

Disclosure legality:

I am not a SEBI Registered individual/entity and the above research article is only for educational purpose and is never intended as trading/investment advice.

Articles

Updated : Mar, 2023

Updated : Mar, 2023

Equity Research Report: Reliance Industries Ltd (RIL...

RIL may scale 2866 by June’23, 3392 by Mar’24, 4017-4758 by Mar’25 amid expected robust O2C, retail, telecom/digital and Oil & gas (E&P) business

Author : ASIS GHOSH

Updated : Mar, 2023

Updated : Mar, 2023

Jubiliant Foodworks Limited

HSBC Webinar with Jubiliant Foodworks Management Meet Note

Author : Krishan Varma

Updated : Mar, 2023

Electronics Mart India Ltd

A Business Analysis

Author : Krishan Varma

Updated : Mar, 2023

Ami Organics Ltd

A Business Analysis

Author : Meghna Rathod

Updated : Jun, 2022

Equity Research Report: Sakar Healthcare

Sakar Healthcare Ltd is engaged in manufacturing of pharmaceutical formulations in the form of liquid injectables, tablets/ capsules, oral liquid syrups, dry powder injectables and syrups. Presently, its domestic sales accounts for 31% of revenues and ...

Author : Akshita

Updated : Jun, 2022

EQUITY RESEARCH REPORT: NEWGEN SOFTWARE

Newgen Software Technologies is a global software Company and is engaged in the business of software product development including designing and delivering end-to-end software solutions covering the entire spectrum of software services from workflow au...

Author : Akshita

Updated : Jun, 2022

Nifty and Bank Nifty Tumbles Due to Weak Global Cues...

Nifty and Bank Nifty tumbles due to weak global cues lead by higher inflation data, higher crude oil prices and weakening currency.

Author : Shalom Martin

Updated : Jun, 2022

Equity Research Report: Shree Renuka Sugar

Shree Renuka Sugars is a global agribusiness and bio-energy corporation. The Company is one of the largest sugar producers in the world, the leading manufacturer of sugar in India, and one of the largest sugar refineries in the world.

Author : Akshita

Updated : Jul, 2022

Equity Research : Tata Consumer Products Limited

TCPL future ambitions remain aggressive, At 17% EPS CAGR over FY22-25e, TCPL should deliver industry-leading growth within indian FMCG.

Author : Shalom Martin

Updated : Jul, 2022

Equity Research: Birlasoft Ltd

Birlasoft, a small-cap IT company, has an upside potential of 35%. The company’s repeated demonstration of ‘walking the talk’ makes us believe that it is on track to achieve its stated target of USD1bn revenue by FY25E.

Author : Shalom Martin

Comments